Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. (FULC) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · FULC · as of Sep 30, 2025
Ownership Breakdown
134
Institutional Holders
▲ 5 vs Q2
$496.11M
Total Inst. Value
▲ $121.61M vs Q2
54.11M
Shares Outstanding
freeFloat 88.71%
53.85M
13F Shares Held
▼ 546,540 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
FULC largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 10.23M | 16.36% | 16.36% | $94.11B | Nov 14, 2025 | — held |
SUVRETTA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 5.38M | 8.60% | 8.60% | $49.51B | Nov 14, 2025 | ▲ 298.1K |
TCG CROSSOVER MANAGEMENT, LLC pharmaceutical preparations | 5.25M | 8.39% | 8.39% | $48.30B | Nov 17, 2025 | — held |
NANTAHALA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 4.67M | 7.47% | 7.47% | $42.97B | Nov 14, 2025 | ▲ 382.5K |
BLACKROCK, INC. pharmaceutical preparations | 3.71M | 5.93% | 5.93% | $34.10B | Nov 12, 2025 | ▼ 672.3K |
VANGUARD GROUP INC pharmaceutical preparations | 3.00M | 4.80% | 4.80% | $27.60B | Nov 7, 2025 | ▼ 147.0K |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 2.43M | 3.89% | 3.89% | $22.37B | Nov 14, 2025 | ▼ 2.16M |
BALYASNY ASSET MANAGEMENT L.P. pharmaceutical preparations | 1.45M | 2.32% | 2.32% | $13.34B | Nov 14, 2025 | ▲ 112.3K |
D. E. SHAW & CO., INC. pharmaceutical preparations | 1.45M | 2.32% | 2.32% | $13.33B | Nov 14, 2025 | ▲ 272.7K |
DIMENSIONAL FUND ADVISORS LP pharmaceutical preparations | 1.30M | 2.08% | 2.08% | $11.95B | Nov 12, 2025 | ▼ 73.3K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
24
Increased
+5.87M shares3
New Positions
first time holders17
Decreased
−4.89M shares0
Sold Out
fully exitedNet shares change (top 50)
+980.9K
+5.87M / −4.89M
Net new holders
+10
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
FULC insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
4
Buy transactions
3
Sell transactions
1.33
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Lehrer-Graiwer Joshua director | Apr 23, 2026 | Award | 64,000 | $8.08 | $517.1K | 64.0K | Form 4 ↗ |
Gould Robert J director | Jan 2, 2026 | Sale | 15,000 | $10.87 | $163.1K | 469.9K | Form 4 ↗ |
Musso Alan A Chief Financial Officer | Feb 2, 2026 | Award | 170,000 | $10.72 | $1.82M | 170.0K | Form 4 ↗ |
Oltmans Curtis Gale Chief Legal Officer | Feb 2, 2026 | Award | 170,000 | $10.72 | $1.82M | 170.0K | Form 4 ↗ |
Gould Robert J director | Feb 2, 2026 | Sale | 15,000 | $10.72 | $160.9K | 454.9K | Form 4 ↗ |
Tourangeau Greg Principal Accounting Officer | Feb 2, 2026 | Award | 57,000 | $10.72 | $611.0K | 57.0K | Form 4 ↗ |
Sapir Alex See Remarks | Feb 2, 2026 | Award | 650,000 | $10.72 | $6.97M | 650.0K | Form 4 ↗ |
Gould Robert J director | Jan 2, 2026 | Sale | 15,000 | $11.87 | $178.1K | 469.9K | Form 4 ↗ |
Oltmans Curtis Gale Chief Legal Officer | Dec 15, 2025 | Sale | 3,452 | $12.92 | $44.6K | 10.3K | Form 4 ↗ |
RA CAPITAL MANAGEMENT, L.P. 10 percent owner | Dec 8, 2025 | Sale | 1,377,020 | $13.33 | $18.36M | 8.85M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Fulcrum Therapeutics, Inc. (FULC) is primarily owned by institutional investors, who hold approximately 99.5% of total shares outstanding. Company insiders own approximately 11.29%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Fulcrum Therapeutics, Inc. is RA CAPITAL MANAGEMENT, L.P., holding approximately 10.23 million shares — equal to 16.36% of outstanding shares — as of September 30, 2025.
A total of 134 institutional investors currently hold FULC stock, with a combined institutional value of approximately $496,105,089 as of the most recent 13F filing period.
Frequently asked questions
FULC ownershipFulcrum Therapeutics, Inc. (FULC) is primarily owned by institutional investors, who hold approximately 99.5% of shares. The largest shareholder is RA CAPITAL MANAGEMENT, L.P. with a 16.36% stake. Company insiders hold 11.29%. Data sourced from SEC Form 13F as of September 30, 2025.